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Chimeric receptors comprising of the T-cell receptor-z cytoplasmic signalling chain fused to an extracellular ligand-binding domain of
a single-chain antibody (scFv) have served as effective tools for redirecting cytotoxic T lymphocytes (CTL) against tumour cells. In this
report, we constructed a chimeric scFv/z gene composed of the variable regions of an HER-2/neu-specific monoclonal antibody
(MAb) joined to the TCR-z chain. The scFv(anti-HER-2/neu)/z chimeric gene was successfully expressed as a functional surface
receptor in the MD.45 CTL hybridoma (MD.45-HER/z). More importantly, the scFv(anti-HER-2/neu)/z receptor was functionally
active, since it triggered cytokine secretion by the MD.45-HER/z cells upon recognition of HER-2/neu-positive (+) tumour cell lines,
or primary tumour cells from patients with HER-2/neu
+ cancers. The MD.45-HER/z-transduced cells also lysed HER-2/neu
+ target
cells in vitro with high specificity. We tested the antitumour efficacy of scFv(anti-HER-2/neu)/z expressing MD.45 cells in severe
combined immunodeficiency disease mice/human and murine tumour models. The adoptively transferred MD.45-HER/z cells both
slowed significantly the growth of human FM3 melanoma or murine ALC leukaemic cells both transfected to express HER-2/neu.
Our data demonstrate the feasibility of redirecting MD.45 CTL with the scFv(anti-HER-2/neu)/z chimeric receptor to respond
specifically against HER-2/neu expressing tumour cells in vitro and in vivo. Moreover, they make it likely that T cells transduced with the
same chimeric gene might be utilised in the treatment of patients with HER-2/neu
+ tumours.
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A general limitation in the use of cellular adoptive immunotherapy
is the difficulty in obtaining high numbers of lymphocytes
specifically responding to autologous tumour cells. Nevertheless,
in some cases, monoclonal antibodies (MAb) against tumour-
associated antigens have been successfully generated (Abken et al,
1998). One approach, merging T-cell functions with antibody
specificity, was to create chimeric receptors composed of a single-
chain variable domains of MAb (scFv) fused to signalling z-chain
of the T-cell receptor (TCR) (Moritz et al, 1994; Altenschmidt et al,
1997; Brocker and Karjalainen, 1997; Maher et al, 2002; Niederman
et al, 2002) or the g-chain of the low-affinity receptors for IgG
(FcgRIII) (Eshhar et al, 1993, 2001; Hwu et al, 1995; Roberts et al,
1998) or IgE (FceRI) (Weijtens et al, 1996; Haynes et al, 2001).
Introduction of such chimeric genes into T cells enables them to
respond in an MHC-independent fashion to an antigen-specific
trigger via these receptors by cytokine production (Altenschmidt
et al, 1997; Eshhar et al, 2001; Maher et al, 2002) and tumour cell
lysis (Eshhar et al, 1993; Moritz et al, 1994; Hwu et al, 1995;
Weijtens et al, 1996).
The HER-2/neu oncogene (also known as ErbB-2) encodes a
185kDa transmembrane protein-receptor with tyrosine kinase
activity and extensive homology to the epidermal growth factor
receptor (Hung and Lau, 1999). HER-2/neu is ubiquitously
expressed in many epithelial tumours and known to be over-
expressed in approximately 30% of all ovarian and breast cancers
(Slamon et al, 1989, 2001), 35–45% of all pancreatic carcinomas
(Yamanaka et al, 1993) and up to 90% of colorectal carcinomas
(Maxwell-Armstrong et al, 1998) and this overexpression was
shown to correlate with aggressiveness of malignancy and poor
prognosis (Slamon et al, 1989; Pauletti et al, 1996). The HER-2/neu
protein appears to be immunogenic because T-lymphocyte
responses to both MHC class I- and class II-restricted epitopes
have been observed (Yoshino et al, 1994; Fisk et al, 1995; Peiper
et al, 1997; Brossart et al, 1998; Rongcun et al, 1999; Sotiriadou
et al, 2001; Baxevanis et al, 2002; Perez et al, 2002). However, the
use of such peptide epitopes for vaccination studies is limited to
only those patients who express the appropriate MHC class I and
class II alleles. The generation of T lymphocytes with a grafted
MHC-independent recognition specificity for HER-2/neu expres-
sing tumour cells could probably circumvent this problem. To this
end the z-chain of the TCR was linked with a scFv derived from a
MAb directed against the human ErbB-2 receptor (Moritz et al,
1994; Altenschmidt et al, 1997). The scFv(ErbB-2)/z fusion gene
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swas stably expressed in murine T lymphocytes that subsequently
could recognise and lyse either mouse cell lines transfected to
express the human ErbB-2 receptor or the human breast cancer
MDA-MB453 cell line constitutively expressing ErbB-2 (Moritz
et al, 1994; Altenschmidt et al, 1997). The same chimeric construct
was recently used for redirecting a human NK cell line against
HER-2/neu
+ tumours (Uherek et al, 2002).
In the present study, we constructed a novel HER-2/neu
recognising chimeric receptor by fusing a scFv derived from an
anti-human HER-2/neu MAb produced by the HB8696 hybridoma
with the z-chain of the TCR. Such chimeric genes were stably
transduced in the murine MD.45 cytotoxic T lymphocytes (CTL)
hybridoma, which could specifically recognise and lyse in vitro
HER-2/neu expressing human tumour cell lines as well as
metastatic tumour cells from different types of cancer. The
transduced MD.45 CTL were also active in vivo in that they
slowed tumour growth in severe combined immuno deficiency
disease (SCID) mouse/human tumour models. Our data support
the use of our scFv(anti-HER-2/neu)/z chimeric receptor in
protocols related to combined cellular and gene therapy of cancer.
MATERIALS AND METHODS
Patients
Patients with metastatic breast and ovarian adenocarcinomas
(stages III and IV) whose tumours expressed HER-2/neu (four of
17 examined; breast Ca, n¼2; ovarian Ca, n¼2) were included in
this study. Ascites from these patients collected during routine
aspirations were provided by the Oncology Department of
Hippocration State Hospital and the Pathological Clinics of Saint
Savas Cancer Hospital under the Institutional Review Boards of
both Institutions.
Cell lines
The human breast cancer SKBR3 and ovarian cancer SKOV3 cell
lines both expressing HER-2/neu (Brossart et al, 1998; Sotiriadou
et al, 2001) as well as the Raji (Burkitt’s lymphoma) and K562
(erythroleukemia) cell lines were purchased from the American
Type Culture Collection (ATCC) (Manassas, VA, USA). The mouse
hybridoma cell lines Myc-9E10.2 secreting a c-myc-specific MAb
(Evan et al, 1985) and HB8696 secreting the MAb 520C9 which
recognises the human c-ErbB-2 oncoprotein (Ward et al, 1989; Shi
et al, 1991) were also purchased from the ATCC. The MD.45 CTL
hybridoma of BALB/c origin was kindly provided by Dr Z Eshhar
(The Weizmann Institute of Science, Rehovot). The human FM3
melanoma cell line and the murine ALC lymphoma cell line were
kindly provided by Dr J Zeuthen (Danish Cancer Society Research
Center, Copenhagen) and by Dr R Kiessling (Microbiology and
Tumour Biology Center, Karolinska Institute, Stockholm) respec-
tively. The ALC cell line was grown in vivo as ascites by serial
passages in C57BL/6 syngeneic mice. All other cell lines were
grown in RPMI-1640 supplemented with 10% fetal bovine serum
(Life Technologies, Gaithersburg, MD, USA), 2mML -Glutamine
and 50mg/ml gentamycin (both from Sigma, St Louis, MO, USA)
(complete medium).
Isolation of tumour cells
This was performed as recently described (Baxevanis et al, 2000).
Ascites were centrifuged at 400g for 5min to sediment cells, which
were further placed on top of a 75% Ficoll–Hypaque gradient,
overlaid on 100% Ficoll–Hypaque, and spun at 700g for 25min.
Tumour cells were collected from the top of 75% Ficoll–Hypaque
and cryopreserved in liquid nitrogen until ready for use. At that
time, cells were carefully thawed, slowly diluted in RPMI-1640 (Life
Technologies, Gaithersburg, MD, USA) and washed. Tumour cells
were assayed only if their viability was over 80%. Phenotype
analysis showed that all tumours were positive after staining with
an anti-HER-2/neu MAb (clone Neu 24.7) and anti-mouse FITC
(both, Becton Dickinson Mountain View, CA, USA) (range of HER-
2/neu expression: 18–92%; see also ‘Results’).
Construction of scFv(anti-HER-2/neu)
Total cellular RNAs were isolated from hybridoma cells HB8696
with the hot-acid phenol method (Brown and Kafatos, 1988;
Mamalaki et al, 1993). Specific first-strand VH- and VL-cDNAs
were synthesised by the primer extension method using M-MLV
reverse transcriptase (Stratagene) and specific oligonucleotide
primers according to EMBO Practical curse (1991). For the
construction of scFv fragment of anti-HER-2/neu, we amplified
specifically the VH- and VL-cDNAs that were then assembled as a
scFv fragment as described (Mamalaki et al, 1993), by using Taq
DNA polymerase (Minotec, Heraclion, Greece). The assembled
scFv fragment was inserted into the phagemid pHEN1 (Hoogen-
boom et al, 1991) which was used to transform E. coli HB2151. The
pHEN1 phagemid contains the c-myc tag peptide and the
produced scFv is thus a tag antibody fragment. All DNA
manipulations were performed according to previously described
techniques (Kabat et al, 1991). DNA sequences were determined by
the dideoxy-chain termination method (Sanger et al, 1977) using
Sequenase version 2.0 (United States Biochemical Cleveland, CH).
Expression and purification of scFv(anti-HER-2/neu)
fragment
HB2151 cells transformed with the pHEN1-scFv(anti-HER-2/neu)
phagemid were grown at 251Ci n2  TY medium containing
100mg/ml ampicillin and 1% glucose. Soluble antibody fragments
were isolated from the culture supernatants after induction with
1m M IPTG for 16h. Expression of scFv antibody fragments was
assessed by size analysis and immunoreactivity. Supernatants
(15ml) from the induced cultures were analysed by electrophoresis
on 12% SDS–polyacrylamide gels (Laemmli, 1970) and the
proteins electrotransferred onto Hybond-C membranes (The
Radiochemical Centre Amersham, UK) for immunoblotting.
Soluble scFv fragments were detected using a serum-free
hybridoma culture supernatant containing MAb 9E10, directed
against the c-myc tag, and HRP-conjugated goat anti-mouse IgG
(1:500 dilution) (DAKO A/S Glostrup Denmark), as previously
described (Hoogenboom et al, 1991). The tagged scFv was purified
on a protein A–Sepharose column using the anti-c-myc tag MAb
9E10, as previously described (Tsantili et al, 1999) .
Immunofluorescence analysis of scFv(anti-HER-2/neu)
binding on tumour cell lines
This was performed in two steps: at first, tumour cells were
harvested and washed in PBS. Then an amount of 100mlo f1:1 0
diluted scFv(anti-HER-2/neu) was added per one million cells and
incubated on ice for 45min. In the second step, tumour cells were
extensively washed to remove excess of scFv(anti-HER-2/neu) and
then incubated for 30min on ice with anti-myc MAb 9E10 followed
by an additional 30min incubation with FITC-conjugated anti-
mouse Fab (1:20 dilution) (DAKO). After two washes in PBS, cells
were analysed on a FACScan (Becton Dickinson) flow cytometer
and calculated using the LYSYS II software (Becton Dickinson).
Construction of the scFv(anti-HER-2/neu)/f chimeric gene
To construct the scFv/z chimeric receptor we used the eukaryotic
expression vector pCDNA3 (Invitrogen). The scFv was amplified
by PCR from the pHEN1 vector and cloned between the Hind III
and BamHI sites. Next, a leader peptide sequence from Ig heavy
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schain was synthesised in vitro and linked to the scFv via the
inherent Pst I site. The CD3 z chain containing 3 aa extracellular
sequence in addition to the transmembrane and cytoplasmic
portion was amplified from the human cDNA clone kindly
provided by Dr GC Tsokos (Walter Reed Army Institute of
Research, Washington DC, USA) and cloned between BamHI and
EcoRI in frame to the scFv. We also inserted a Flag epitope in the
BamH1 site in order to monitor the expression of the product. The
chimeric scFv/z gene was subsequently digested by Hind III and
EcoRI and cloned (as a blunt fragment) into the retroviral vector
pLRNL containing the long terminal repeat from Moloney murine
leukaemic virus and a neomycin resistance gene. The retroviral
constructs were transfected into the amphotropic cell line Phoenix
(Pear et al, 1993) using CaPO4. A stable amphotropic packaging
cell line, Phoenix, was obtained after G418 selection. The
amphotropic virus supernatants produced had a viral titre of
approximately 5 10
3CFUml
 1, determined on the basis of
neomycin resistance of infected NIH-3T3 cells. Such supernatants
were collected and stored at  201C.
Gene transduction and selection of gene-transduced cells This
was performed as described previously (Weijtens et al, 1996). In
brief, 2 10
6 cells of the MD.45 hybridoma cell line were
cocultured for 72h with a 70–80% confluent irradiated
(2500rad) monolayer of virus pLRNLscFv(anti-HER-2/neu)/z
producing Phoenix cells in culture medium supplemented with
4mgml
 1 polybrene (Sigma Chemical Co., St Louis, MO, USA) and
500IUml
 1 rIL-2. Subsequently, the gene-transduced MD.45
population (MD.45-HER/z) was selected for 4 days in culture
medium containing 1mgml
 1 G418, followed by an additional
round of selection (5 days) in medium containing 0.4mgml
 1
G418. After selection, the MD.45-HER/z cells were expanded in
round-bottom 96-well microtitre plates (Costar, Cambridge, MA,
USA) at 371Ci n5 %C O 2 in the presence of feeder cells, which
consisted of irradiated (2500rad) allogeneic EBV-transformed
lymphoblastoid B cell lines. Cloning of the MD.45-HER/z cells was
performed by limiting dilution at 3,1 and 0.3 cellswell
 1 in the
presence of feeder cells in RPMI-1640 culture medium supple-
mented with 10% FCS, 300IUml
 1 rIL-2, 4mML -glutamine,
antibiotics and 1mgml
 1 PHA (Sigma). Mock-transduced MD.45
cells (MD.45-mock) were generated by transducing the parental
MD.45 cell line with the vector (i.e., pLRNL) alone.
Transfection of the FM3 and ALC cell lines
This was performed as described recently (Perez et al, 2002). In
brief, FM3 melanoma cells were cotransfected with a pSV2-c-erbB2
construct (kindly provided by Dr. Mien-Chie Hung, Anderson
Cancer Center, Houston, TX, USA) and a pSV2neo plasmid using
DNA-CaPO4 coprecipitates. Selection with G418 was performed 2
days later, followed by cloning and subcloning of FM3 cells
expressing HER-2/neu (referred to as FM3-HER). The same
procedure was followed for transfecting the ALC cells with the
pSV2-c-erbB2 construct (referred to as ALC-HER). Mock-trans-
fectants of FM3 (FM3-mock) and ALC (ALC-mock) were generated
by transfecting the parental cell lines with the plasmid (i.e., pSV2)
alone.
Expression of the chimeric scFv(anti-HER-2/neu)/f gene
Expression of the scFv(anti-HER-2/neu)/z on the surface of
transduced MD.45 cells was evaluated by indirect immunofluor-
escence staining using the anti-Flag MAb (Sigma) and FITC-
labelled anti-mouse Fab0 antibody. Data were analysed and
calculated as above.
Functional assays
These included cytokine production and cytotoxicity: transduced
MD.45 cells (10
6) were cultured with 10
6 HER-2/neu
+ or HER-2/
neu
  cell lines in 24-well plates (Costar) for 24h. Following
incubation, supernatants were harvested and spun to remove cell
debris. Levels of cytokine production (IL-2 and IFN-g) were
measured by ELISA (Diaclone Research, Besancon, France)
according to the manufacturer’s instructions.
Cytotoxicity mediated by the MD.45-transduced effectors
against tumour HER-2/neu
+ or HER-2/neu
  targets was deter-
mined as described (Baxevanis et al, 2000). The percentage of
cytotoxicity was calculated according to the following formula: %
lysis¼100 (test
51Cr release–spontaneous
51Cr release)/(max-
imum
51Cr release–spontaneous
51Cr release). Cytotoxicity values
were considered to indicate significant recognition of a target,
when the differences between mean values (from triplicate
analyses) for percent lysis of the particular target (e.g., HER-2/
neu
+ tumour cell targets) and HER-2/neu
  targets were equal to or
higher than 10% at an E:T ratio of 20:1 and statistically
significant (Po0.05).
Tumour therapy model
All the in vivo experimentations were carried out with approval
form the ethical committee of St Savas Cancer Hospital and
met all the standards required by the UKCCCR guidelines
(Workman et al, 1998). The tumour therapy model was performed
as follows: on day 1, CB-17 Prkdcscid /J (BALB/c scid) mice
(Jackson Laboratory, Bar Harbor, Maine, Germany) 7–9 weeks
of age received 1 10
6 tumour cell s.c. injection. MD.45-HER/z
or MD.45-mock CTL was injected i.p. (1 10
7 cells injection
 1)
on three consecutive days (starting on day 1). Total observation
was over 120 days. The observation was terminated with the
euthanasia of mice when the tumour mass grew up to 1.5cm in
diameter.
RESULTS
Construction of scFv(anti-HER-2/neu)
Specific VL- or VH-cDNAs of hybridoma HB8696 mRNA,
enzymatically amplified, were assembled as scFv antibody frag-
ment and cloned into pHENI vector (Hoogenboom et al, 1991).
The primary structure of various clones was analysed by DNA
sequencing. Figure 1A shows the cDNA sequence and the deduced
amino-acid sequences corresponding to the VH region of MAb
520C9. Sequence comparison showed that the VH region of MAb
520C9 is a member of the subgroup IIA according to Kabat et al
(1991). The complementarity-determining region 2 (CDR2) is
long, containing 17 amino-acid residues. Figure 1B shows the
cDNA sequence and the deduced amino-acid sequences corre-
sponding to the VL region of MAb 520C9. Sequence comparison
showed that the VL region is a member of the Vk group (Kabat
et al, 1991).
Reactivity of the anti-HER-2/neu scFv with tumour cell
lines and primary tumour cells
Binding of the scFv(anti-HER-2/neu) on tumour cells was
determined by immunofluorescence and FACS analysis. Cell
immunofluorescence was performed with ALC and FM3 tumour
cell lines transfected to express HER-2/neu (ALC-HER and FM3-
HER, respectively), their mock transfectants and with the SKBR3
and SKOV3 tumour cell lines constitutively expressing HER-2/neu.
Primary HER-2/neu
+ tumour cells from patients with metastatic
breast (Br-1, Br-2) and ovarian (OVA-1, OVA-2) cancer were also
analysed. The Raji and K562 cell lines, not expressing HER-2/neu,
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swere included as negative controls. As shown in Figure 2, the
ALC-HER, FM3-HER, SKBR3 and SKOV3 tumour cell lines were
positive in immunofluorescence staining with the scFv(anti-HER-
2/neu) and anti-myc MAb plus FITC-anti-mouse Fab0 system
(86%, 68%, 100% and 89%, respectively) and so did the primary
tumour cells from metastatic breast (Br-1, 92%; Br-2, 27%) and
ovarian (OVA-1, 81%; OVA-2, 18%) cancers. In contrast, ALC-
mock and FM3-mock as well as Raji and K562 cell lines did not
show positive staining demonstrating the ability of our scFv to
specifically bind on HER-2/neu
+ cells.
Expression of the chimeric scFv(anti-HER-2/neu)/f gene
Expression of the chimeric scFv(anti-HER-2/neu)/z receptor
selective for HER-2/neu
+ tumour cells was performed by
constructing one continuous molecule comprising gene segments
of the variable region of the murine anti-HER-2/neu MAb
produced by the HB8696 hybridoma and the signal-transducing
human TCR-z chain transmembrane and intracellular region.
Introduction of the chimeric scFv(anti-HER-2/neu)/z gene into the
MD.45-murine CTL hybridoma, resulted in the expression of the
GAGGTGCAGCTGCAGGAGTCAGGGCCTGAGCTGAAGAAGCCTGGAGAGACAGTCAAGATC  +60
GluValGlnLeuGlnGluSerGlyProGluLeuLysLysProGlyGluThrValLysIle
 1 5  10   15     20
TCCTGCAAGGCTTCTGGATATACCTTCGCAAACTATGGAATGAACTGGATGAAGCAGGCT  +120
SerCysLysAlaSerGlyTyrThrPheAlaAsnTyrGlyMETAsnTrpMETLysGlnAla
 21       25  30    35     40
CCAGGAAAGGGTTTAAAGTGGATGGGCTGGATAAACACCTACACTGGACAGTCAACATAT  +180
ProGlyLysGlyLeuLysTrpMETGlyTrpIleAsnThrTyrThrGlyGlnSerThrTyr
 41       45  50    55     60
GCTGATGACTTCAAGGAACGGTTTGCCTTCTCTTTGGAAACCTCTGCCACCACCGCCCAT  +240
AlaAspAspPheLysGluArgPheAlaPheSerLeuGluThrSerAlaThrThrAlaHis
61       65  70    75    80
TTGCAGATCAACAACCTCAGAAATGAGGGCTCGGCCACATATTTCTGTGCAAGACGATTT  +300
LeuGlnIleAsnAsnLeuArgAsnGluGlySerAlaThrTyrPheCysAlaArgArgPhe
81       85  90    95     100
GGGTTTGCTTACTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA                +345
GlyPheAlaTyrTrpGlyGlnGlyThrThrValThrValSerSer
101      105 110   115
GACATTGAGCTCACCCAGTCTCCAGCCTCCCTTTCTGCGTCTGTGGGAGAAACTGTCACC  +60
AspIleGluLeuThrGlnSerProAlaSerLeuSerAlaSerValGlyGluThrValThr
 1 5  10   15     20
ATCACATGTCGAGCAAGTGGGAATATTCACAATTATTTAGCATGGTATCAGCAGAAACAG  +120
IleThrCysArgAlaSerGlyAsnIleHisAsnTyrLeuAlaTrpTyrGlnGlnLysGln
 21       25  30    35     40
GGAAAATCTCCTCAGCTCCTGGTCTATTATACAACAACCTTAGCAGATGGTGCGCCATCA  +180
GlyLysSerProGlnLeuLeuValTyrTyrThrThrThrLeuAlaAspGlyAlaProSer
 41       45  50    55     60
AGGTTCAGTGGCAGTGGATCAGGAACACAATATTCTCTCAAGATCAACAGCCTGCAACCT  +240
ArgPheSerGlySerGlySerGlyThrGlnTyrSerLeuLysIleAsnSerLeuGlnPro
61       65  70    75     80
GAAGATTTTGGGAGTTATTACTGTCAACATTTTTGGAGTACTCCTCGGACGTTCGGTGGA  +300
GluAspPheGlySerTyrTyrCysGlnHisPheTrpSerThrProArgThrPheGlyGly
81       85  90    95     100
GGGACCAAGCTGGAAATAAAACGG
GlyThrLysLeuGluIleLysArg
101      105
CDR1
CDR2
CDR3
CDR1
CDR2
CDR3
A
B
Figure 1 Nucleotide and deduced protein sequences of the heavy (A) and light (B) chain variable domain of MAb 520C9. The CDRs 1, 2 and 3 are
indicated.
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schimeric molecule on the cell surface of selected clones as revealed
after staining with the anti-Flag-FITC MAb (Figure 3).
Cytokine secretion by the MD.45-HER/f cells upon
recognition of HER-2/neu
+ tumour cells or cell lines
The functionality of the chimeric receptor was examined by testing
the ability of MD.45-HER/z cells to secrete IL-2 and IFN-g upon
interaction with HER-2/neu
+ cells. As presented in Table 1, 24h
incubation of MD.45-HER/z cells with the SKOV3 and SKBR3
HER-2/neu
+ tumour cell lines resulted in secretion of relatively
high levels of IL-2 (40–100 fold higher compared to background
levels (i.e., those achieved with the MD.45-mock cells). That the
interaction between MD.45-HER/z CTL with the tumour cell target
was specific for HER-2/neu was best shown using the HER-2/neu
transfectants. Thus, recognition of both ALC-HER and FM3-HER
by the MD.45-HER/z cells resulted in 10-fold higher secretion of
IL-2 as compared to the IL-2 levels secreted upon recognition of
their mock transfectants. Recognition of HER-2/neu
+ primary
tumour cells isolated from patients’ ascites led to 15- to 30-fold
increased secretion of IL-2 levels as compared to background
levels (Table 1). Finally, interaction of MD.45-HER/z cells with
HER-2/neu
  K562 and Raji cell lines induced only marginal IL-2
secretion comparable to background levels. The specificity of
interaction between MD.45-HER/z hybridoma CTL and HER-2/neu
expressing tumour cell lines or primary tumour cells was also
confirmed by the fact that an anti-HER-2/neu MAb when present
throughout the 24h incubation period substantially blocked IL-2
secretion (range of % inhibition: 64–90) (Table 1).
A similar profile for IFN-g secretion was observed in the same
cultures. Thus, the SKBR3 and SKOV3 HER-2/neu-overexpressing
tumour cell lines, the HER-2/neu transfectants or the primary
HER-2/neu
+ tumour cells stimulated increased secretion of IFN-g
by the MD.45-HER/z transduced CTL hybridoma (Table 2). IFN-g
secretion was also greatly inhibited in the presence of the anti-
HER-2/neu MAb (% range of inhibition: 69–85) (Table 2).
Cytotoxic activity of MD.45-HER/f cells
The functional expression of the scFv(anti-HER-2/neu)/z receptor
on transduced MD.45 CTL hybridoma was further tested in
cytotoxicity experiments against a panel of HER-2/neu
+ and HER-
2/neu
  tumour cell lines. As shown in Figure 4, all tumour targets
expressing HER-2/neu were lysed at relatively high levels (range of
% cytotoxicity at E/T ratio of 20: 37–67). Lysis of HER-2/neu
 
tumour targets was always at very low levels and ranged between 5
and 10% (E/T:20). That indeed the specificity of lysis was governed
by functional expression of the scFv(anti-HER-2/neu)/z chimeric
gene was further demonstrated (i) by the inhibition of lysis of
HER-2/neu
+ targets following the addition of the anti-HER-2/neu
MAb (range of % inhibition: 55–92) and (ii) by the inability of
MD.45-mock effectors to lyse HER-2/neu
  targets. Finally that the
killing mediated by MD.45-HER/z was non-MHC-restricted can be
concluded from the fact that HER-2/neu
+ targets from unrelated
allogeneic donors were as efficiently lysed as the murine ALC-HER
cells.
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Figure 2 FACS analysis of immuofluorescence staining of HER-2/neu
+
(ALC-HER, FM3-HER, SKBR3, SKOV3) and HER-2/neu
  (ALC-mock, FM3-
mock, Raji, K562) tumour cell lines, treated with scFv(anti-HER-2/neu) and
anti-myc MAb plus FITC-labelled anti-mouse Fab0 antibody. Ova-1, Ova-2,
Br-1 Br-2 are HER-2/neu
+ primary tumour cells from patients with
metastatic ovarian and breast cancer. Solid lines: specific staining with
scFv(anti-HER-2/neu) plus anti-myc and FITC-anti-mouse Fab0; dotted lines:
staining with anti-myc and FITC-anti-mouse Fab0.
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Figure 3 FACS analysis of immunofluorescence staining of MD.45 hybridoma transduced with pLRNLscFv(anti-HER-2/neu)/z (MD.45-HER/z) or with the
vector alone (MD.45-mock). Expression of scFv(anti-HER-2/neu)/z was detected with an anti-Flag MAb plus FITC-labelled anti-mouse Fab0 (solid lines).
Dotted lines: staining with FITC-labelled anti-mouse Fab0 alone.
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+ tumour cells in SCID mice
To assess whether MD.45-HER/z cells had significant in vivo
activity against HER-2/neu
+ tumour cells, 1 10
6 murine ALC-
HER lymphoma cells or an equal number of human FM3-HER-
melanoma cells were inoculated s.c. in SCID mice that had been
irradiated (200rad) 1 day before to suppress endogenous NK
activity. On the same day with tumour cell inoculation and for the
following 2 days, mice were treated with i.p. injections (one
injection per day) of MD.45-HER/z or MD.45-mock-transduced
cells. Mice treated with MD.45-HER/z cells experienced a
significantly prolonged survival as compared to those treated with
MD.45-mock cells (for both models 4100 days; Po0.001)
(Figure 5). The specificity of recognition of ALC-HER or FM3-
HER in vivo by the MD.45-HER/z cells was shown by the inability
of the later to prevent ALC-mock or FM3-mock growth in the SCID
mice (Figure 5).
DISCUSSION
The HER-2/neu oncoprotein may serve as an excellent target for
developing anticancer agents specific for HER-2/neu overexpres-
sing cancer cells. This is based on previously published observa-
tions confirming its in vivo and in vitro role as an immunogenic
protein. Thus, CTL responses specific for MHC class I HER-2/neu
epitopes have been observed in some patients with cancer and
HER-2/neu-specific IgG antibodies have been detected in the sera
of patients with HER-2/neu
+ cancers (Disis et al, 1994a,b; Yoshino
et al, 1994; Knutson et al, 2001). Furthermore, tumour-reactive
CTL- and helper T-cell responses could be induced in vitro using
various recently identified MHC class I- or class II-binding
peptides (Peiper et al, 1997; Brossart et al, 1998; Kobayashi et al,
2000; Sotiriadou et al, 2001; Baxevanis et al, 2002; Perez et al,
2002). Adoptive cellular immunotherapy utilizing patients’ T
lymphocytes primed in vitro to recognise HER-2/neu epitopes
represents one major modality for treating patients carring HER-2/
neu
+ tumours. In preclinical models, infusion of HER-2/neu
reactive T cells in animals developing HER-2/neu
+ tumours has led
to tumour eradication (Knutson et al, 2002). However, adoptive T-
cell therapy in patients with HER-2/neu
+ cancers was relatively
unsuccessful due, in part, to the inability to expand tumour
antigen-specific T- cells ex vivo.
To circumvent the limitations associated with the expansion of
HER-2/neu
+ tumour-specific T cells, we have adopted an approach
in which T lymphocytes are grafted with a permanent antibody-
dictated specificity (Eshhar et al, 2001). To this end, we have
provided the z-chain of TCR with an extracellular recognition
domain (scFv) from an anti-HER-2/neu MAb produced by the
HB8696 hybridoma. This chimeric construct was stably integrated
Table 1 Optimal IL-2 secretion of transduced MD.45-HER/z CTL upon target cell interaction
a
IL-2 production (pgml
 1)
Targets
HER-2/neu
expression
b MD.45-HER/f MD.45-HER/f+Neu 24.7 MD.45-mock
ALC-mock
c F 2275
d 1973 (13)
e o10
ALC-HER
c + 290750 5576 (81) 2776
FM3-mock
c F 37783 9 77(  5) 32710
FM3-HER
c + 368732 67712 (82) 3976
SKBR3 + 10457220 375752 (64) o10
SKOV3 + 9607180 295727 (69) 2375
OVA-1
f + 235710 52717 (78) o10
OVA-2
f + 182732 39722 (78) o10
Br-1
f + 650775 105723 (90) 4278
Br-2
f + 268729 106717 (60) o10
K562 F o10 o10 (0) o10
Raji F 27762 8 79(  3) o10
aMD.45 CTL transduced with scFv(anti-HER-2/neu)/z (MD.45-HER/z) was cultured at 1 10
6cells ml
 1 with an equal
number of tumour cell targets for 24h in 24-well plates in 1ml total volume per culture. IL-2 production in the supernatant
was measured by ELISA. MD.45-pLRNL is the mock-transduced MD.45 CTL (MD.45-mock). MD.45-HER/z or MD.45-
mock CTL cultured in the absence of tumour targets produced less than 20pgml
 1 IL-2. Tumour cells cultured alone
produced less than 15pgml
 1 IL-2.
bHER-2/neu expression was determined as described in ‘Materials and Methods’.
cTransfected ALC and FM3 cells to express HER-2/neu (ALC-HER, FM3-HER) and their mock transfectants (ALC-mock,
FM3-mock).
dMean values7s.d. from three independently performed experiments.
ePercent inhibition of IL-2 production in
the presence of 10mgml
 1 of anti-HER-2/neu mAb (Neu 24.7), added at culture initiation, was calculated as follows:
IL-2 pg=ml w=omAb   IL-2pg=ml with mA   bIL-2pg=ml w=omAb 100:
fPrimary tumour cells collected from perito-
neal effusions during routine aspirations from patients with metastatic breast (Br-1, Br-2) and ovarian (OVA-1, OVA-2)
cancer.
Table 2 Optimal IFN-g secretion of transduced MD.45-HER/z CTL
upon target cell interaction
IFN-c production (pgml
 1)
Targets MD.45-HER/f MD.45-HER/f+Neu 24.7 MD.45-mock
ALC-mock o10 o10 o10
ALC-HER 87772 3 76 (73) o10
FM3-mock o10 o10 o10
FM3-HER 6979 o10 o10
SKBR3 290738 45712 (84) o10
SKOV3 320742 72716 (77) o10
OVA-1 95713 2977 (69) 1772
OVA-2 165728 6876 (59) o10
Br-1 77762 3 73 (70) o10
Br-2 92772 8 76 (69) 2076
K562 o10 o10 o10
Raji o10 o10 o10
See footnotes of Table 1. IFN-g production of either cell type (i.e., transduced MD.45
cells or tumour cell targets) was always o10pgml
 1.
Antitumour activity of receptor-transduced hybridoma cells
AD Gritzapis et al
1297
British Journal of Cancer (2003) 88(8), 1292–1300 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sand expressed by retroviral gene transfer in the MD.45 CTL
hybridoma. MD.45 cells transduced to express the scFv(anti-HER-
2/neu)/z could specifically recognise HER-2/neu
+ breast and
ovarian tumour cell lines as well as HER-2/neu
+ primary tumour
cells from patients with metastatic breast and ovarian cancer. Such
recognition led to lysis of HER-2/neu
+ tumour targets and also to
secretion of IL-2 and IFN-g by the MD.45-HER effector CTL. The
combined induction of cytokine secretion and cytotoxicity by the
redirected MD.45 cells is an important issue supporting the use of
our chimeric receptor gene for transducing patients’ PBL to be
used in cellular adoptive immunotherapy. In this way, besides
direct tumour cell lysis by transduced CD8
+ T cells, release of
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Figure 5 Survival of SCID mice after subcutaneous injection (day 1) with human melanoma FM3 (FM3-HER, FM3-mock) or murine leukaemic ALC (ALC-
HER, ALC-mock) cell lines. On the same day (day 1) and for the following 2 days (days 2 and 3) mice were treated with PBS or MD45 cells transduced
either with scFv(anti-HER-2/neu)/z (MD.45-HER/z) or with their mock tranfectants (MD.45-mock). In all cases, mice treated with MD.45-HER/z
demonstrated a significant increase in survival compared to the other groups (Po0.01).
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Figure 4 Cytotoxicity of MD.45-HER/z and MD.45-mock cells against HER-2/neu
+ (ALC-HER, FM3-HER, SKBR3, SKOV3, Ova-1, Ova-2, Br-1, Br-2) and
HER-2neu
  (ALC-mock FM3-mock, K562, Raji) targets tested in a 4h cytotoxicity assay. Blocking of cytolysis mediated by MD.45-HER/g cells was
performed with an anti-HER-2/neu MAb (Neu 24.7) at a concentration of 10mgml
 1. The specific
51Cr release is depicted at E/T:20. Mean values from
triplicate cultures are shown. The s.d. (not shown) never exceeded 10% of the mean values. Results from one representative experiment out of three
performed are shown.
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+ T cells upon specific target cell
interaction may also contribute to tumour growth inhibition as
well as induction of NK/LAK activities. These lytic activities may
result in elimination of tumour cells that lack- or downregulate the
relevant (i.e., HER-2/neu) tumour-associated antigen (Pawelec
et al, 1997).
Chimeric constructs containing a single-chain antibody directed
against the human ErbB-2 receptor have been previously demon-
strated to redirect T-cell specificity towards mouse epithelial cells
transformed to express the human ErbB-2 and human ErbB-2
+
MDA-MB453 breast cancer cells (Moritz et al, 1994; Altenschmidt
et al, 1997). In these studies, the recognition function was
contributed by the scFv domain derived from the MAb FRP5
(Wels et al, 1992), specific for the extracellular domain of ErbB-2,
whereas the z-chain of the TCR represented the signalling
component. In the present study, we designed a new construct
using the scFv from another anti-HER-2/neu Mab produced by the
HB8696 hybridoma. Competitive inhibition studies on HER-2/
neu
+ tumours utilizing both FRP5- and HB8696-derived scFvs (one
FITC-conjugated and the other nonlabelled) could probably clarify
whether these recognise the same or different HER-2/neu epitopes.
However, irrespective of the epitope recognised, our MD.45
effectors transduced to express this particular scFv (fused to the
TCR z-chain) were capable of recognising and lysing HER-2/neu
+
tumour cell lines from different types of cancer as well as primary
HER-2/neu
+ tumour cells from metastatic breast and ovarian
cancers. Given the fact that MD.45 cells expressing this construct
were also active in vivo by inhibiting the growth of HER-2/neu
+
tumour cells (see below), it becomes evident that our HER/z
construct offers a novel and promising tool for future therapeutic
interventions in cancer.
The in vivo antitumour activity of MD.45-HER/z was evaluated
in SCID mice/tumour models. Murine ALC or human FM3 tumour
cells either transfected to express HER-2/neu or mock-transfected
were inoculated into SCID mice. MD.45-HER/z cells, when
implanted simultaneously with the HER-2/neu
+ tumour cells and
for the following 2 days (one injection per day) considerably
slowed the growth of these tumour cells. MD.45-HER/z cells did
not exhibit any therapeutic effect when mice were inoculated with
ALC or FM3 tumour cells not expressing HER-2/neu (i.e., ALC-
mock or FM3-mock cells) indicating the specificity of the in vivo
antitumour response. This was confirmed by demonstrating the
inability of MD.45-mock cells to slow the growth of ALC-HER or
FM3-HER tumour cells in SCID mice. Another interesting point
which came out from our studies is that the MD.45-HER/z cells
must have the ability to traffic and target tumour cells in vivo,
since these were given i.p., whereas both the ALC and FM3 tumour
cells were given s.c. It is also important to note that the in vivo
antitumour activity was observed in the absence of exogenously
added IL-2 demonstrating that the IL-2 (and most probably also
IFN-g) produced by the MD.45-HER/z cells upon encounter of the
tumour cells (as shown in the in vitro experiments) was sufficient
for supporting their in vivo activity. This is an important issue
since, clinically, IL-2 administration has been associated with
significant toxicity (Rosenberg et al, 1994). Finally, although
survival was enhanced three-fold, all mice eventually died from
their ALC-HER
+ or FM3-HER
+ tumours. FACS analysis of these
tumour cells showed continued presence of HER-2/neu expression
(data not shown). This suggests that antigen downregulation was
not the mechanism of escape in this particular model. Another
possibility, although not tested herein, could be that the injected
MD.45-HER/z effectors underwent IL-2 dependent, Fas-mediated
activation-induced cell death.
Complete tumour eradication may require repeated treatment,
combination of i.p. and i.v. therapy, or combinations with other
treatment approaches. With respect to this, therapy strategies
using a second round of injections with MD.45-HER/z cells 1
month after tumour cell inoculation or combined treatment with
HER-2/neu peptide-specific CTL and MD.45-HER/z cells are under
investigation in our laboratory. Tumour therapy using a variety of
chimeric receptors targeting different antigens may also be
necessary should antigen downregulation or in vivo immunoselec-
tion of HER-2/neu negative cells becomes evident.
In summary, the data from this report describe a novel chimeric
receptor construct for the gene therapeutic approach to HER-2/
neu
+ cancers. The cells expressing this chimeric construct respond
specifically to HER-2/neu
+ tumours in vitro and are also
therapeutically effective in vivo. Current efforts are focused on
enhancing transduction efficiencies and chimeric gene expression
in primary T cells, as well as bone marrow stem cells, to maximise
the applicability of this technology.
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